To the best of our knowledge, this study is the first NMA to assess and compare the prophylactic benefits of individual GLP-1 receptor agonists and SGLT2 inhibitors on metastatic cancers with various origins. The gene discussed is GLP1R; the disease is metastatic malignant neoplasm.